The FDA has warned consumers not to purchase unapproved GLP-1 drugs, including products containing Semaglutide, tirzepatide, or retatrutide that are falsely labeled for research purposes or not for human consumption
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), a class of glucose-lowering drugs, have demonstrated a wide range of pleiotropic effects that extend beyond glycaemic control
The plaintiffs and the defendant corporations will interview experts, like doctors, who can talk about Trulicity, GLP-1s, and gastroparesis
All included studies investigated subcutaneously administered GLP-1 agonists
Yes, Trulicity (dulaglutide) can cause skin rash, though this side effect is uncommon
Conclusion In this single-centre retrospective cohort study of Chinese patients with obesity treated with naltrexone-bupropion, we observed a mean of 10% body weight loss achieved by 6 months, which was maintained over the 12 months of follow-up